Table 1 Information on patients who contracted hypokalemic periodic paralysis from systemic glucocorticoid administration

Our case

1

26

M

1.7

Dexamethasone, IM

Within 24 hours

First

No

N/A

Arzel-Hézode M. et al. (2009) [10]

2

36

M

2.7

Methylprednisolone, 48 mg PO

Within 24 hours

First

Yes

SCN4A, R675Q

3

23

M

1.4

Methylprednisolone, 48 mg PO

Within 24 hours

One previous

No

SCN4A, R675W

4

26

M

1.9

Methylprednisolone, 120 mg IV

Within 24 hours

First

No

No mutation found

5

25

M

2.49

Methylprednisolone, 120 mg IV

Within 24 hours

First

N/A

No mutation found

6

N/A

M

2.1

Prednisone, 60 mg PO

Within 24 hours

First

No

No mutation found

7

20

M

2

Prednisone, 60 mg PO

N/A

First

Yes

No mutation found

8

31

M

2

Methylprednisolone, 100 mg IV

Within 24 hours

One previous

No

No mutation found

9

16

M

2.7

Prednisolone, 60 mg PO

Within 24 hours

First

Yes

SCN4A, R672H

10

15

F

N/A

Methylprednisolone, 16 mg PO

N/A

First

No

CACNA1, R528H

11

16

M

2.2

Prednisolone, 80 mg PO

Within 24 hours

First

No

Kir, KCNJ2, C54F

12

27

M

2.4

Prednisone, 60 mg PO

Within 24 hours

First

No

SCN4A, R1451C

13

35

M

0.8

Prednisolone, 80 mg PO

8 days

One previous

Yes

CACNA1, R528H

Corey M. Teagarden et al. (2011) [7]

14

23

F

1.6

Betamethasone, 12 mg IM for two times

Within 24 hours

First episode

No

N/A

J. Casey Elkins (2019) [8]

15

27

M

1.5

Dexamethasone, IV

N/A

Two previous

N/A

N/A

S.R. Harter et al. (2019) [9]

16

33

M

1.9

Methandienone, a C17-alpha alkylated steroid

Decadron, 250 mg IM daily

N/A

First

N/A

N/A

Ana Catarina Carvalho et al. (2019) [23]

17

15

M

1.9

Methylprednisolone

N/A

First

Yes

N/A